Zymeworks Inc (ZYME) FinancialsZYMEZymeworks Inc

Evaluating the bottom line, Zymeworks Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -918.95%, while the net margin is -980.81%. These profitability ratios, combined with a Return on Equity (ROE) of -72.31%, provide a clear picture of how effectively ZYME converts its operational activities into shareholder value.

In the context of the broader market, ZYME competes directly with industry leaders such as BHVN and GPCR. With a market capitalization of $1.80B, it holds a leading position in the sector. When comparing efficiency, ZYME's gross margin of 100.00% stands against BHVN's N/A and GPCR's N/A. Such benchmarking helps identify whether Zymeworks Inc. is trading at a premium or discount relative to its financial performance.

Zymeworks has shown a gross margin of 100% consistently over the past quarters, indicating strong profitability on its products. However, it has faced significant net losses, with a net income of -45,019,000 USD in Q2 2026, highlighting ongoing financial challenges.